Advertisement
News
Subscribe to MDT Magazine News

Third Rock Ventures launches Blueprint Medicines with $40M

April 11, 2011 6:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Blueprint Medicines, a Cambridge early-stage cancer therapeutics firm, has scored a $40 million Series A funding round from Boston's Third Rock Ventures, the largest A round financing the venture capital firm has ever made.

Survey Finds Mobility Providers Struggling to Adjust to New Medicare Policies and Regulations

April 11, 2011 6:35 am | by Bio-Medicine.Org | Comments

WASHINGTON, April 11, 2011 /PRNewswire-USNewswire/ -- A survey of home medical equipment companies released today found that many businesses providing power wheelchairs to Medicare beneficiaries have made abrupt changes in their operations to comply with new federal policies.  But...

TOPICS:

Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels

April 11, 2011 6:34 am | by Bio-Medicine.Org | Comments

MAPLE GROVE, Minn., April 11, 2011 /- Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in...

TOPICS:
Advertisement

Baptist Health of Northeast Florida Acquires Brainsuite® iMRI and Brainsuite® iCT Digitally Integrated ORs

April 11, 2011 6:32 am | by Bio-Medicine.Org | Comments

WESTCHESTER, Ill., April 11, 2011 /- Baptist Health of Northeast Florida will be the first health system in North America to offer intra-operative imaging during pediatric and adult brain surgery and non-surgical radiosurgical procedures with the Brainlab Brainsuite® iMRI...

TOPICS:

Mauna Kea Technologies Announces Highlights of Third International Conference of Cellvizio Users (ICCU)

April 11, 2011 6:32 am | by Bio-Medicine.Org | Comments

NICE, France, April 11, 2011 /- Mauna Kea Technologies today announced highlights from the 3rd Annual International Conference of Cellvizio® Users (ICCU).  The meeting included 32 different speakers and 25 posters on the role and impact of probe-based confocal laser...

TOPICS:

Malpractice Movement Calls for Reporting Directly to Patients, Part 2 in a Series

April 11, 2011 5:34 am | by Diagnostic Imaging | Comments

Communication - or failure to communicate - is an important issue in radiology malpractice lawsuits. However, in the past, radiologists have not been the primary communicators of imaging reports with patients, as that has been the responsibility of the referring physician. That is about to change.

TOPICS:

PositiveID Corporation Announces Positive Results From Its Easy Check Breath Glucose Detection Device in Preliminary Laboratory Testing

April 11, 2011 5:34 am | by PositiveID | Comments

PositiveID Corporation Announces Positive Results From Its Easy Check Breath Glucose Detection Device in Preliminary Laboratory Testing

TOPICS:

Researchers find replacement for rare material indium tin oxide

April 11, 2011 3:37 am | by I-Micronews | Comments

Researchers at Eindhoven University of Technology have developed a replacement for indium tin oxide (ITO), an important material used in displays for all kinds of everyday products such as TVs, telephones and laptops, as well as in solar cells.

Advertisement

Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer

April 11, 2011 3:36 am | by Bio-Medicine.Org | Comments

MALVERN, Pa., April 11, 2011 /- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc. (Pfizer), following the first sale of XIAPEX in...

TOPICS:

Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®

April 11, 2011 3:35 am | by Bio-Medicine.Org | Comments

ROCKVILLE, Md., April 11, 2011 /- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) announced today that Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable (or depot) formulation of...

TOPICS:

Clinical study suggests estrogen levels and breast health can be altered

April 11, 2011 3:32 am | by EurekAlert | Comments

(Strategic Communications) Researchers from Canada and the United States today told attendees of the Experimental Biology 2011 Scientific Meeting that they have uncovered a possible means of enabling women to favorably influence whether the estrogens in their bodies take a "beneficial...

TOPICS:

Ligand to Achieve Profitability for 1st Time, Chief Says

April 10, 2011 11:34 pm | by San Diego Business Journal | Comments

Ligand Pharmaceuticals Inc. is on track for its first profitable year, said Rob McKay, the biotech's senior director of business development.

TOPICS:

ViaCyte Takes Kyoto Laureate's Work to Next Level

April 10, 2011 11:33 pm | by San Diego Business Journal | Comments

A San Diego company that is working to bring to market a treatment for diabetes derived from embryonic stem cells is also working with Kyoto Prize winner Shinya Yamanaka

TOPICS:

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

April 10, 2011 11:33 pm | by Bio-Medicine.Org | Comments

WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /- Merck (NYSE: MRK ), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an...

TOPICS:

New review suggests drinking 100 percent fruit juice may offer disease-fighting benefits

April 10, 2011 9:33 pm | by EurekAlert | Comments

(Kellen Communications) Highlights from a new report summarizing recent research on the potential benefits of 100 percent fruit juice suggest a positive association between intake of 100 percent juice and reduced risk for several chronic diseases, including cancer, markers for...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading